PepKon Advances Oncology Innovation as a Finalist at MEET2WIN 2024

PepKon recently participated in the 9th edition of MEET2WIN, the premier oncology innovation convention organized by MATWIN. This event served as a key platform for groundbreaking developments in peptide-based cancer therapies and oncological peptide drug development.

As one of the 12 finalists selected through the MATWIN accelerator program, Philippe Karoyan, our scientific co-founder, and Jonathan Levy, our CEO, had the opportunity to present PepKon’s latest advancements in AI-driven peptide drug discovery and computational peptide modeling to Matwin’s board.

We extend our gratitude to MATWIN and Unicancer for organizing this event, providing an exceptional opportunity to showcase our expertise in peptide therapeutics development and oncology-focused peptide engineering.

The connections made at MEET2WIN reinforce our commitment to advancing peptide-based drug discovery and targeted peptide cancer treatments.

We look forward to leveraging these insights and collaborations to drive the next generation of peptide-based oncology treatments, bringing innovative solutions to patients worldwide.

‍